Sixth Meeting of the North American Drug Dialogue
By: Public Safety Canada
Ottawa – November 9, 2022
The following joint statement was released by the Governments of Canada, Mexico and the United States of America.
Senior officials from Canada, Mexico and the United States met on November 7 and 8, 2022 in Ottawa and virtually, for the Sixth North American Drug Dialogue (NADD). A result of the 2016 North American Leaders' Summit (NALS), the NADD is the principal mechanism through which our three countries address current and emerging drug threats facing North America.
At the November 2022 meeting, representatives from the three countries reviewed progress since the Fifth NADD meeting in February 2022, with particular attention paid to trends in trafficking of illegal drugs and commercial disruption to address the ways in which criminals exploit the legitimate commercial supply chain. The three countries also agreed to a path forward for the NADD that expands our cooperation and updates our strategic objectives. This fulfills a commitment made by the Prime Minister of Canada and the Presidents of Mexico and the United States at the November 2021 NALS and is expected to support strengthened collaboration to address illegal drugs and associated public health and safety concerns.
In 2023, the three countries will continue and enhance our work to:
Strengthen our public health approaches related to prevention, harm reduction, treatment, and recovery services;
understand and address the illegal supply chain of illegal synthetic drugs and their precursor chemicals and related equipment affecting North America, especially those causing the most harm to our populations;
address drug trafficking via multiple modes of transport; and,
better understand and address the illegal drug-related financing methods and activities that support operating capital, access and profit from illegal drug sales, and facilitate new and existing partnerships amongst the relevant stakeholders.
Canada hosts North American Leaders' Summit
Fifth Meeting of the North American Drug Dialogue